The University at Buffalo is monitoring the COVID-19 (the disease caused by the novel coronavirus) situation carefully and is taking proactive and prudent measures to ensure the health and safety of the UB community in accordance with the guidance provided by the Centers for Disease Control and Prevention (CDC).
Our David Chu Lecture, scheduled for April 30, 2020, has been postponed.
We will be posting more updates as they become available. Thank you.
Considerations in the Discovery of Small Molecule Kinase Inhibitors for the Treatment of Brain Tumors and the Discovery of GDC-0084
Presented by Timothy Heffron, PhD
Discovery Chemistry, Genetech, Inc.
Dr. Heffron is a Principal Scientist and Associate Director in the Discovery Chemistry Department at Genentech. Dr. Heffron has contributed to numerous small molecule drug discovery programs leading to the discovery of eight Clinical Development Candidates (including taselisib--Ph3 and GDC-084--Ph2).
Dr. Heffron’s expertise spans small molecule therapeutics for oncology, neurology, and ophthalmic indications. Dr. Heffron is the co-author of more than 50 publications or issued patents and was the recipient of the David Robertson Award from the American Chemical Society for seminal contributions to the field of medicinal chemistry. Dr. Heffron received his undergraduate degree in chemistry from Yale University and his PhD in organic chemistry from MIT.
C. K. David Chu, PhD, and his wife, Jane Chu, established the David Chu Lectureship at UB in 2011.
David Chu is a distinguished research professor emeritus of pharmaceutical and biomedical sciences at the College of Pharmacy, University of Georgia. He earned a PhD in medicinal chemistry from the University at Buffalo in 1975 under the mentorship of Professor Thomas Bardos. Dr. Chu was one of the co-founders of Pharmasset and ATEA Pharmaceuticals. During his 40-year career, Dr. Chu trained more than 130 graduate students and postdoctoral fellows and has maintained an active research program in drug design and synthesis since his retirement in 2008. He has published over 300 peer-reviewed articles in organic, biochemical and medicinal chemistry and has been awarded more than 60 US patents. Several of his invented compounds are undergoing clinical trials in the therapeutic areas of cancer, hepatitis B virus, HIV and shingles.
An elected member of the American Association of Advancement of Science and the National Academy of Inventors, Dr. Chu received the Antonin Holy Memorial Lecture Award from the International Society Antiviral Research and the Willis G. Gregory Award from the UB School of Pharmacy in 2017. He also received the Alma Mater of the Year Award from Seoul National University in 2015, the John A. Montgomery Award from the International Round Table Society in 2014, a MERIT Award from the National Institute of Health in 2001, and the UGA Inventor of the Year Award in 2002.